Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

HER-2 and topoisomerase II as predictors of response to chemotherapy.

Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B.

J Clin Oncol. 2008 Feb 10;26(5):736-44. doi: 10.1200/JCO.2007.15.4716. Review.

PMID:
18258981
[PubMed - indexed for MEDLINE]
Free Article
2.

Predictive factors for anthracycline-based chemotherapy for human breast cancer.

Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S.

Breast Cancer. 2010 Apr;17(2):103-9. doi: 10.1007/s12282-009-0152-6. Epub 2009 Aug 6. Review.

PMID:
19657712
[PubMed - indexed for MEDLINE]
3.

Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?

Di Leo A, Isola J.

Clin Breast Cancer. 2003 Aug;4(3):179-86. Review.

PMID:
14499010
[PubMed - indexed for MEDLINE]
4.

New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.

Gennari A, Pronzato P.

Clin Breast Cancer. 2008 Dec;8 Suppl 4:S179-83. doi: 10.3816/CBC.2008.s.015. Review.

PMID:
19158039
[PubMed - indexed for MEDLINE]
5.

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. Review.

PMID:
19365520
[PubMed - indexed for MEDLINE]
Free Article
6.

HER2/neu in systemic therapy for women with breast cancer: a systematic review.

Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M.

Breast Cancer Res Treat. 2008 May;109(2):209-29. Epub 2007 Jul 17. Review.

PMID:
17636396
[PubMed - indexed for MEDLINE]
7.

Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge.

Munro AF, Cameron DA, Bartlett JM.

Oncogene. 2010 Sep 23;29(38):5231-40. doi: 10.1038/onc.2010.286. Epub 2010 Aug 2. Review.

PMID:
20676126
[PubMed - indexed for MEDLINE]
8.

Predicting anthracycline benefit: have we made any progress?

Moretti E, Oakman C, Di Leo A.

Curr Opin Oncol. 2009 Nov;21(6):507-15. doi: 10.1097/CCO.0b013e328331a501. Review.

PMID:
19713842
[PubMed - indexed for MEDLINE]
9.

The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.

Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.

Cancer Treat Rev. 2009 Dec;35(8):662-7. doi: 10.1016/j.ctrv.2009.08.006. Epub 2009 Sep 15. Review.

PMID:
19758759
[PubMed - indexed for MEDLINE]
10.

Anthracyclines in early-stage breast cancer: is it the end of an era?

Robson D, Verma S.

Oncologist. 2009 Oct;14(10):950-8. doi: 10.1634/theoncologist.2008-0070. Epub 2009 Jun 26. Review. Erratum in: Oncologist. 2009 Dec;14(12):1252.

PMID:
19561291
[PubMed - indexed for MEDLINE]
Free Article
11.

The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.

Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V.

Cancer Treat Rev. 2007 Feb;33(1):64-77. Epub 2006 Nov 17. Review.

PMID:
17113234
[PubMed - indexed for MEDLINE]
12.

Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?

Romero A, Caldés T, Díaz-Rubio E, Martín M.

Clin Transl Oncol. 2012 Mar;14(3):163-8. doi: 10.1007/s12094-012-0779-1. Review.

PMID:
22374418
[PubMed - indexed for MEDLINE]
13.

The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.

Jacot W, Fiche M, Zaman K, Wolfer A, Lamy PJ.

Biochim Biophys Acta. 2013 Aug;1836(1):146-57. doi: 10.1016/j.bbcan.2013.04.004. Epub 2013 Apr 26. Review.

PMID:
23628726
[PubMed - indexed for MEDLINE]
Free Article
14.

Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.

Tsakonas G, Kosmas C.

J BUON. 2007 Jul-Sep;12(3):319-27. Review.

PMID:
17918284
[PubMed - indexed for MEDLINE]
15.

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

Di Leo A, Biganzoli L, Claudino W, Licitra S, Pestrin M, Larsimont D.

Eur J Cancer. 2008 Dec;44(18):2791-8. doi: 10.1016/j.ejca.2008.09.014. Epub 2008 Nov 5. Review.

PMID:
18993056
[PubMed - indexed for MEDLINE]
16.

Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.

Järvinen TA, Liu ET.

Cytopathology. 2003 Dec;14(6):309-13. Review.

PMID:
14632727
[PubMed - indexed for MEDLINE]
17.

Using specific cytotoxics with a targeted mind.

Di Leo A, Claudino WM, Pestrin M, Licitra S, Biganzoli L.

Breast. 2007 Dec;16 Suppl 2:S120-6. Epub 2007 Aug 27. Review.

PMID:
17720501
[PubMed - indexed for MEDLINE]
18.

Role of anthracyclines in the treatment of early breast cancer.

Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN.

J Clin Oncol. 2009 Oct 1;27(28):4798-808. doi: 10.1200/JCO.2008.21.4791. Epub 2009 Aug 17. Review.

PMID:
19687331
[PubMed - indexed for MEDLINE]
Free Article
19.

Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?

Petrelli F, Cabiddu M, Ghilardi M, Barni S.

Expert Opin Investig Drugs. 2009 Oct;18(10):1467-77. doi: 10.1517/13543780903222268. Review.

PMID:
19737114
[PubMed - indexed for MEDLINE]
20.

A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.

Sekine I, Shimizu C, Nishio K, Saijo N, Tamura T.

Int J Clin Oncol. 2009 Apr;14(2):112-9. doi: 10.1007/s10147-008-0813-z. Epub 2009 Apr 24. Review.

PMID:
19390941
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk